Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil slashes TB mortality but 70,000 cases keep it a top priority

This article was originally published in Clinica

Executive Summary

The incidence of tuberculosis in Brazil has fallen by almost 26% in the last 10 years but the disease remains a major diagnostic priority for the government. The number of new cases fell from almost 83,000 in 1999, to 70,380 in 2008, and TB-related mortality fell by 34.2% between 1999 and 2007. However, the disease remains the country's fourth-leading infections-related cause of death. A secondary benefit of the national TB detection programme, reports the health ministry, has been to improve the detection of HIV. Last year, the percentage of HIV cases detected through testing done in response to a TB diagnosis stood at over 45%, compared with under 26% in 2001.

You may also be interested in...



US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel